SCHEMBL2073435

SCHEMBL2073435

[16O]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL595356 1.00
SCHEMBL8037345 1.00
SCHEMBL176061 1.00
SCHEMBL822 1.00
Phosphine SCHEMBL20477183 1.00
SCHEMBL9177548 1.00
SCHEMBL1459105 0.71
SCHEMBL9185475 0.71
Fluoride SCHEMBL9130872 0.71
SCHEMBL8204904 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 587 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260062446-A1 SCALABLE SYNTHESIS OF ANABAENOPEPTINS WAYNE STATE UNIVERSITY (US) 2026-03-05 US claimed
CN-119988995-A Ancient biological data identification platform 中国地质科学院地质研究所 2025-05-13 CN claimed
CN-119186260-A Method for replacing oxygen isotopes from carbon monoxide 中国原子能科学研究院 2024-12-27 CN claimed
CN-115716661-B Process for preparing oxygen 16 enriched metal oxides 中国原子能科学研究院 2024-03-22 CN claimed
CN-115716661-A Method for producing oxygen 16-enriched metal oxide 中国原子能科学研究院 2023-02-28 CN claimed
EP-4747387-A1 COAGULATION FACTOR XI-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF Adarx Pharmaceuticals, Inc. (US) 2026-05-27 EP disclosed
CN-113164489-B Inhibitors of VAP-1 ACUCELA INC. (US) 2026-05-26 CN disclosed
EP-3976600-B1 NON-HYGROSCOPIC CRYSTALLINE SALTS OF A PYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITIONS AND USE THEREOF YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2026-05-20 EP disclosed
EP-4743118-A1 FUNCTIONALIZED AURISTATINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Surio Therapeutics Co. Ltd (CN) 2026-05-20 EP disclosed
US-12633426-B2 Method for determining real-time thermal power of a nuclear reactor based on number of gamma rays counted MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2026-05-19 US disclosed
CN-121578570-B Method and device for inhibiting ultraviolet laser damage of fused quartz optical element 中国工程物理研究院激光聚变研究中心 2026-05-15 CN disclosed
US-20260130928-A1 COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN ASCENTAWITS PHARMACEUTICALS LTD (CN) 2026-05-14 US disclosed
US-11266651-B2 Pharmaceutical compositions and methods of treating cardiovascular diseases CARDIX Therapeutics, LLC (US) 2022-03-08 US disclosed
WO-2022046905-A1 CRF RECEPTOR ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2022-03-03 WO disclosed
US-20220056488-A1 MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF AROMATICS, 2,4-PENTADIENOATE AND 1,3-BUTADIENE GENOMATICA INC (US) 2022-02-24 US disclosed
US-20220040169-A1 Methods for the Administration of Certain VMAT2 Inhibitors NEUROCRINE BIOSCIENCES, INC. 2022-02-10 US disclosed
WO-2022031925-A1 ULTRA EFFICIENT ACCELERATOR PRODUCTION OF ISOTOPICALLY PURE ACTINIUM-225 CRYORAD, INC. (US) 2022-02-10 WO disclosed
US-11242352-B2 Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer CAPELLA THERAPEUTICS, INC. (US) 2022-02-08 US disclosed
US-20220024915-A1 INHIBITORS OF VAP-1 ACUCELA INC. 2022-01-27 US disclosed
US-7897400-B2 Non-invasive rapid diagnostic test for M. tuberculosis infection STC.UNM (US) 2011-03-01 US disclosed